Skip to main navigation Skip to search Skip to main content

Extended interval dosing of natalizumab in multiple sclerosis

  • L. Zhovtis Ryerson
  • , T. C. Frohman
  • , J. Foley
  • , I. Kister
  • , B. Weinstock-Guttman
  • , C. Tornatore
  • , K. Pandey
  • , S. Donnelly
  • , S. Pawate
  • , R. Bomprezzi
  • , D. Smith
  • , C. Kolb
  • , S. Qureshi
  • , D. Okuda
  • , J. Kalina
  • , Z. Rimler
  • , R. Green
  • , N. Monson
  • , T. Hoyt
  • , M. Bradshaw
  • J. Fallon, E. Chamot, M. Bucello, S. Beh, G. Cutter, E. Major, J. Herbert, E. M. Frohman
  • New York University
  • University of Texas Southwestern Medical Center
  • Rocky Mountain MS Clinic
  • Georgetown University
  • Barnabas Health
  • City University of New York
  • Vanderbilt University
  • University of Massachusetts Medical School
  • Multiple Sclerosis Center of Connecticut
  • University of Alabama at Birmingham
  • SUNY Buffalo
  • National Institutes of Health
  • University of Texas at Dallas

Research output: Contribution to journal › Article › peer-review

141 Scopus citations

Abstract

Background: Natalizumab (NTZ), a monoclonal antibody to human α4 β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions with a hypothesis of reducing PML risk. The aim of the study is to evaluate the clinical consequences of reducing NTZ frequency of infusion up to 8 weeks 5 days. Methods: A retrospective chart review in 9 MS centres was performed in order to identify patients treated with extended interval dosing (EID) regimens of NTZ. Patients were stratified into 3 groups based on EID NTZ treatment schedule in individual centres: early extended dosing (EED; n=249) every 4 weeks 3 days to 6 weeks 6 days; late extended dosing (LED; n=274) every 7 weeks to 8 weeks 5 days; variable extended dosing (n=382) alternating between EED and LED. These groups were compared with patients on standard interval dosing (SID; n=1093) every 4 weeks. Results: 17% of patients on SID had new T2 lesions compared with 14% in EID (p=0.02); 7% of patients had enhancing T1 lesions in SID compared with 9% in EID (p=0.08); annualised relapse rate was 0.14 in the SID group, and 0.09 in the EID group. No evidence of clinical or radiographic disease activity was observed in 62% of SID and 61% of EID patients (p=0.83). No cases of PML were observed in EID group compared with 4 cases in SID cohort. Conclusions: Dosing intervals up to 8 weeks 5 days did not diminish effectiveness of NTZ therapy. Further monitoring is ongoing to evaluate if the risk of PML is reduced in patients on EID.

Original languageEnglish
Pages (from-to)885-889
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume87
Issue number8
DOIs
StatePublished - Jan 8 2016

Fingerprint

Dive into the research topics of 'Extended interval dosing of natalizumab in multiple sclerosis'. Together they form a unique fingerprint.

Cite this